Sign in
Not yet taking people in United StatesPhase 1/2

Tests a non-surgical approach for breast cancer after chemotherapy

Tests whether breast cancer patients who respond well to chemotherapy can avoid surgery.

Key facts

Who runs it
Ohio State University Comprehensive Cancer Center
Where
Columbus, United StatesSee the site
Trial code
Registry title
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
84 people, planned
Starts
15 Jan 2027
Expected to end
31 Jan 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Neoadjuvant Chemotherapy
  • Radiation Therapy
  • MRI
  • Breast Cancer Surgery
  • Biopsy
  • Biospecimen collection
Record updated
9 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with early-stage breast cancer of the HER2-positive or triple negative type who plan to have chemotherapy before surgery and radiation. It tests whether some people can avoid surgery.

Age
18 years or older
Sex
Men and women
Disease stage
Early-stage breast cancer (cT1-3 N0 or cT1-2 N1) that is HER2-positive or triple negative
Earlier treatment
Planning to receive chemotherapy before surgery (neoadjuvant chemotherapy) and radiation therapy
Biomarker or test result
HER2-positive or triple negative tumor type

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Extensive calcifications in the breast (complex cases are discussed by the study doctors)
  • Skin involvement or distant metastases
  • Inmate or prisoner
  • Treatment with an investigational drug or other intervention during breast cancer treatment

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18 years or older
  • Early-stage breast cancer diagnosis (cT1-3 N0 or cT1-2 N1) and a Human Epidermal Receptor 2 (HER2)-positive or triple negative breast cancer (TNBC) tumor molecular subtype
  • Cannot have extensive calcifications in the breast (for complex cases, a patient with calcification's eligibility will be discussed by the study co-principal investigators (PIs) and the treating physicians)
  • Planning to receive neoadjuvant chemotherapy (NAC) and radiation therapy (RT)

Who cannot take part

  • Treatment with an investigational drug or other intervention throughout their breast cancer treatment
  • Pregnancy or lactation
  • Inmate or prisoner
  • Patients with skin involvement and/or distant metastases

Where in United States

  • Ohio State University Comprehensive Cancer CenterColumbus, United StatesContact: Sachin Jhawar, MDNot yet recruiting

About the trial

What the trial wants to find out

This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.

The 2 groups in the trial

  • Arm A (eeCR, non-surgical)Treatment being tested

    Patients will receive standard of care (SOC) neoadjuvant chemotherapy and will be evaluated for enhanced clinical complete response (ecCR) after treatment. Participants who achieve an ecCR will be placed in the non-surgical arm. Participants will receive radiation therapy and routine and additional screening MRIs during follow up.

    Treatment: Neoadjuvant Chemotherapy, Radiation Therapy, MRI, Biopsy, and Biospecimen collection

  • Arm B (non-eeCR, surgical)Treatment being tested

    Patients will receive standard of care (SOC) neoadjuvant chemotherapy and will be evaluated for enhanced clinical complete response (ecCR) after treatment. Participants who do not achieve an ecCR will be placed in the surgical arm. Participants will undergo a lumpectomy or mastectomy, receive radiation therapy, and routine follow-up.

    Treatment: Neoadjuvant Chemotherapy, Radiation Therapy, MRI, Breast Cancer Surgery, Biopsy, and Biospecimen collection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
Plain-language title
Tests a non-surgical approach for breast cancer after chemotherapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
9 November 2026